Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3314)	12/13/1997 4:48:00 PM
From: David S.	Read Replies (1) \| Respond to of 6136

You really are too funny.

To: JOHN W. who wrote (3314)	12/15/1997 8:21:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

"Nelfinavir Boosts Bioavailability of Saquinavir in HIV-Positive Patients" Reuters Health Information Services (12/12/97) ÿÿÿÿ A group of U.K. and Irish researchers, led by David Black of the University of Liverpool, recently found that the use of two protease inhibitors with two nucleoside analogues helps boost protease inhibitor bioavailability to the therapeutic range among some patients. According to the study, published in the December issue of AIDS, the use of nelfinavir raises the bioavailability of saquinavir by five times. In the study, that was conducted with six HIV-positive patients, Black and his colleagues first provided a three-drug combination therapy, and then added nelfinavir three times daily for two days. The team concluded that for some patients, the use of nelfinavir boosted the efficacy of the drug levels to the therapeutic range. However, the variability among patients' baseline plasma saquinavir levels indicates that most effective dosing should be individualized.